
SUTRO BIOPHARMA, INC.
93
Recent news highlights include encouraging early clinical activity from the STRO-004 Phase 1 study and multiple analyst coverage initiations with positive outlooks. The company’s stock has experienced volatility with notable price movements reported in early 2026.
- Sutro announced encouraging early clinical activity from the STRO-004 Phase 1 study, with dosing progressing through multiple cohorts as of early 2026 [N1].
- Multiple analyst firms initiated coverage of Sutro Biopharma with positive recommendations during 2026, reflecting interest in the company’s pipeline and platform [N2][N3][N4].
- The company’s stock experienced notable price movements including surges of 11.9% in February 2026 and 7.4% in April 2026, indicating market attention to clinical and financing developments [N7][N8].
Sutro Biopharma operates as a clinical-stage oncology company focused on developing novel antibody drug conjugates (ADCs) enabled by its proprietary XpressCF® and XpressCF+® cell-free protein synthesis platforms. These platforms allow rapid and precise production of homogeneous ADCs with site-specific conjugation of cytotoxic payloads, aiming to improve therapeutic indices over conventional heterogeneous ADCs. The company’s lead product candidate, STRO-004, targets tissue factor (TF) and is undergoing Phase 1 clinical evaluation for multiple solid tumors. Sutro also develops other ADC candidates including STRO-006 and STRO-227, with IND filings planned. The company has established collaborations with pharmaceutical leaders such as Astellas, Merck, Bristol Myers Squibb, and EMD Serono to leverage its platform technology. Sutro’s strategy includes advancing clinical programs, expanding partnerships, and broadening its pipeline of next-generation protein therapeutics.
Sutro Biopharma, Inc. is a clinical-stage oncology company specializing in the development of site-specific antibody drug conjugates (ADCs) using proprietary cell-free protein synthesis platforms. The company’s lead candidate, STRO-004, is in Phase 1 clinical trials targeting tissue factor-expressing solid tumors. Sutro maintains multiple collaborations with major pharmaceutical companies and has a diversified pipeline including preclinical ADC candidates. As of September 30, 2026, the company reported $46.85 million in cash, $95.33 million in short-term investments, and a net loss of $31.49 million for the quarter. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sutro’s proprietary cell-free protein synthesis platforms enable the development of next-generation ADCs with improved therapeutic indices, potentially addressing unmet needs in oncology. The advancement of STRO-004 through Phase 1 clinical trials and the initiation of IND-enabling activities for other pipeline candidates demonstrate progress in execution. Collaborations with leading pharmaceutical companies provide validation of the platform’s capabilities and potential for expanded development opportunities. The company’s strong liquidity position supports ongoing research and development activities.
Sutro faces risks typical of clinical-stage biopharmaceutical companies, including the inherent uncertainties of clinical trial outcomes and regulatory approvals. The discontinuation of prior programs such as STRO-002 indicates challenges in product development. Dependence on collaborations may expose the company to strategic shifts by partners, as seen with terminations of clinical development by some collaborators. Financial losses and negative earnings per share reflect ongoing investment needs without current product revenues. Market competition and technological advancements by others in the ADC space may also impact Sutro’s prospects.
Sutro Biopharma’s moat derives from its proprietary XpressCF® and XpressCF+® platforms, which enable rapid, scalable, and site-specific conjugation of ADCs with homogeneous product profiles. This technology addresses key limitations of conventional ADCs, such as heterogeneity and suboptimal payload positioning, potentially leading to improved efficacy and safety profiles. The platform’s ability to incorporate multiple non-natural amino acids and dual payloads (e.g., immunostimulatory and cytotoxic) provides a technological edge. Additionally, Sutro’s established collaborations with major pharmaceutical companies and its substantial payments received from these partnerships support its competitive positioning in the oncology biologics space.
• Clinical Development Risk: STRO-004 and other pipeline candidates are in early clinical or preclinical stages, with inherent uncertainties regarding safety, efficacy, and regulatory approval.
• Collaboration Dependency: Sutro’s business relies on partnerships with pharmaceutical companies, which may terminate or alter development plans, affecting Sutro’s pipeline and revenue.
• Financial Risk: The company reports net losses and negative earnings per share, requiring continued capital to fund operations and development programs.
• Competitive Landscape: The ADC field is competitive with multiple approved products and candidates; technological advances by competitors may challenge Sutro’s platform advantages.
Business trends: Advancement of site-specific ADCs leveraging proprietary cell-free protein synthesis platforms with focus on STRO-004 and next-generation ADC modalities.
Execution milestones: Progression of STRO-004 Phase 1 clinical trial dosing, IND enabling activities for STRO-006 and STRO-227, and maintenance of strategic collaborations.
Key risks: Clinical development uncertainties, reliance on partner collaborations, ongoing financial losses, and competitive pressures in the ADC oncology market.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Sutro Biopharma, Inc. is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates (ADCs) using proprietary integrated cell-free protein synthesis platforms XpressCF® and XpressCF+® [S1].
- The company focuses on therapeutics modalities including ADCs, bispecific ADCs, immunostimulatory ADCs (iADCs), and dual-payload ADCs (dpADCs) targeting clinically validated cancer targets with suboptimal current treatments [S1].
- Sutro's lead wholly-owned product candidate is STRO-004, a homogeneous ADC targeting tissue factor (TF) for solid tumors, with a Phase 1 trial initiated in November 2025 and dosing ongoing through early 2026 [S1].
- The Phase 1 trial of STRO-004 is open-label, multicenter, dose-escalation, evaluating safety, pharmacokinetics, and preliminary anti-tumor activity in advanced TF-expressing solid tumors including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer [S1].
- Preclinical assets include STRO-006 (ADC targeting integrin alpha v beta 6) with IND enabling activities underway and STRO-227 (dual-payload ADC targeting PTK7) with IND filing anticipated in late 2026 or early 2027 [S1].
- Sutro has multiple collaborations with pharmaceutical companies including Astellas, Merck, Bristol Myers Squibb (Celgene), and EMD Serono for development of ADCs and related modalities [S1].
- The company has received approximately $1.016 billion in payments from collaborations through December 31, 2025, including $79 million in stock investments [S1].
- Sutro discontinued development of STRO-002 (luveltamab tazevibulin) in March 2025 following a strategic portfolio review [S1].
- The company’s proprietary XpressCF® platform is cGMP compliant and scalable, enabling rapid protein production (less than 24 hours) compared to conventional methods (30-40 days), and allows incorporation of multiple non-natural amino acids for site-specific conjugation [S1].
- Sutro’s technology aims to overcome limitations of conventional ADCs such as heterogeneity, suboptimal linker-warhead positioning, lack of tumor specificity, and payload mechanism limitations by enabling homogeneous ADCs with precise conjugation and dual payloads [S1].
- The company’s strategy includes advancing STRO-004 through clinical development, pursuing strategic partnerships, developing a diverse pipeline of novel protein therapeutics, and expanding collaborations to maximize platform value [S1].
- As of September 30, 2026, Sutro reported cash and equivalents of $46.85 million, short-term investments of $95.33 million, current assets of $159.5 million, current liabilities of $54.31 million, a current ratio of 2.94, and a cash ratio of 2.62 [S2].
- For the quarter ended September 30, 2026, Sutro reported a net loss of $31.49 million and basic and diluted EPS of -$1.90 per share [S2].
- Recent news includes announcements of encouraging early clinical activity from the STRO-004 Phase 1 study and multiple analyst coverage initiations with positive outlooks [N1][N2][N3][N4][N7][N8].
Generated 2026-11-13
- S1 | 2026-03-23 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/upstream-bio-inc-upb-reports-q3-loss-lags-revenue-estimates
- N2 | 2026-11-02 | www.nasdaq.com | Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/axsome-therapeutics-axsm-reports-q3-loss-tops-revenue-estimates
- N3 | 2026-08-11 | www.nasdaq.com | Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/upstream-bio-inc-upb-reports-q2-loss-tops-revenue-estimates
- N4 | 2026-08-06 | www.nasdaq.com | BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/bioage-labs-inc-bioa-reports-q2-loss-beats-revenue-estimates
- N5 | 2026-05-06 | www.nasdaq.com | MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/mannkind-mnkd-reports-q1-loss-misses-revenue-estimates
- N6 | 2026-05-05 | www.nasdaq.com | Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/ocugen-ocgn-reports-q1-loss-beats-revenue-estimates
- N7 | 2026-04-09 | www.nasdaq.com | RLAY Hits 52-Week High, MPLT Nears Lockup Expiry; ORKA Makes EVERLASTing Gains | https://www.nasdaq.com/articles/rlay-hits-52-week-high-mplt-nears-lockup-expiry-orka-makes-everlasting-gains
- N8 | 2026-04-01 | www.nasdaq.com | Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains? | https://www.nasdaq.com/articles/wave-life-sciences-wve-surges-95-indication-further-gains
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


